Ironwood Pharmaceuticals Beats Q3 2026 Estimates, Raises Full-Year Guidance Again

As seen on the 24/7 Wall St. homepage on November 5, 2026.

IRWD Ironwood Pharmaceuticals
Q3 2026
EPS
$0.36
est $0.31 +16.1%
Revenue
$133M
est $122M +9.4%

A $623 million company just raised full-year guidance for the second straight quarter, lifting LINZESS U.S. net sales to $1.20 billion to $1.25 billion. Operating cash flow nearly tripled to $130.8 million.

Continue ReadingShow less

Ironwood Pharmaceuticals posted adjusted earnings of $0.36 per share for Q3 2026, clearing the consensus estimate of $0.31 by 16%. Revenue of $133.04 million also surpassed analyst expectations of $121.57 million by about 9%, and was up 9% from the same quarter a year ago. The back-to-back beats show a company that has re-established a consistent pattern of outperformance after a choppy 2024 and early 2025.

The engine behind both results is LINZESS, the irritable bowel syndrome treatment Ironwood develops in collaboration with AbbVie. U.S. net sales for the full brand reached $324.92 million in the quarter, with prescription volume growing 4.9% year over year to 63.4 million capsules, according to IQVIA data. The commercial margin on LINZESS expanded to 79.8% from 75.9% a year ago, meaning more of each dollar of sales is reaching the bottom line.

Operating cash flow was the other standout number: $130.8 million in the quarter, compared with $47.6 million in Q3 2025, a gain of roughly 175% year over year. That cash generation allowed Ironwood to repay $60 million on its revolving credit facility, bringing the principal outstanding to $325 million. SG&A also fell sharply to $11.6 million from $21.9 million, reflecting the January 2025 strategic reorganization.

Sponsored

On the strength of those results, management raised full-year 2026 guidance for the second consecutive quarter. The updated outlook calls for LINZESS U.S. net sales of $1.20 billion to $1.25 billion, total revenue of $485 million to $510 million, and adjusted EBITDA above $350 million. CEO Tom McCourt said year-to-date U.S. net sales have already surpassed all of 2025, adding that the company believes LINZESS is on its way to returning to blockbuster status for 2026.

Beyond LINZESS, the company is ramping its STARS-2 confirmatory Phase 3 trial of apraglutide in short bowel syndrome with intestinal failure, targeting activation of more than 100 sites across 22 countries. All planned international clinical trial applications have been submitted and are under review or approved. Subject to those results, Ironwood is targeting a regulatory filing for apraglutide in 2029. Separately, McCourt will hand the CEO role to Tammi Gaskins effective January 1, 2027, introducing a leadership transition investors will be watching alongside the pipeline milestones.

Mentioned: IRWD